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ABSTRACT
Subcutaneous immunoglobulin (SCIG) treatment 
provides stable serum immunoglobulin G (IgG) 
levels, is associated with fewer systemic adverse 
events than intravenous immunoglobulin 
(IVIG) treatment, and offers the convenience 
of home therapy. In clinical practice, IVIG 
is still used preferentially for initiation of 
treatment in newly diagnosed patients with 
primary immunodeficiency (PI) and for 
immunomodulatory therapy, such as treatment 
of peripheral neuropathies, when high doses are 
believed to be necessary. The authors discuss 
recent experience in using SCIG in place of IVIG 
in these settings. SCIG has been successfully used 
for initiation of therapy in previously untreated 
PI patients. Seventeen of 18 PI patients achieved 
serum IgG levels ≥5 g/L after the loading phase. 
Daily treatment was well tolerated and provided 
opportunities for patient/parent training in self-
infusion. SCIG has been used for maintenance 
therapy in multifocal motor neuropathy (MMN) 
in three recent clinical trials, with good efficacy 
and tolerability results. Seven of eight MMN 
patients maintained serum IgG levels of 14-22 g/L 
with a mean dose of 272 mg/kg/week, had 
stable muscle strength, and felt comfortable 
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with self-administration. Four patients with 
polymyositis or dermatomyositis achieved 
improvement in serum creatine kinase levels 
and muscle strength with SCIG therapy. Recent 
experience with SCIG suggests that traditional 
concepts of immunoglobulin therapy may be 
challenged to increase available therapy options. 
SCIG can be used to achieve high IgG levels 
within several days in untreated PI patients 
and to maintain high serum levels, as shown in 
patients with MMN.
Keywords: immunoglobulin G; immunoglobulin 
therapy; multifocal motor neuropathy; primary 
immunodeficiencies; serum levels; subcutaneous 
administration
INTRODUCTION
Intravenous immunoglobulin (IVIG) has been the 
preferred route of therapy for primary immune 
deficiencies since the early 1980s. Subcutaneous 
immunoglobulin (SCIG) administration was 
first described by Bruton in 1952.1 Later, 
SCIG administration with small pumps was 
introduced in the United States (US) and became 
widely used in Sweden and Norway.2-4 Positive 
treatment experience increased the popularity 
of the subcutaneous route among physicians 
and patients elsewhere.5,6 SCIG therapy obviates 
the need for venous access, maintains stable 
serum IgG levels, offers fewer systemic adverse 
events (AEs) when compared to IVIG, and 
is amenable to self-infusion.7-9 Self-infusion 
and home administration allow flexibility in 
adapting to the patient’s own schedule and 
are associated with improved quality of life 
compared to hospital or office-based intravenous 
treatment.10-12
Recent IVIG products are still given mostly 
at a clinic, doctor’s office, or infusion center. 
Recently developed SCIG preparations offer more 
rapid infusion in addition to good efficacy and 
tolerability. These technological advancements 
prompt reconsideration of the use of SCIG in 
different indications currently reserved for IVIG.
In current practice, SCIG has mainly been 
used for maintenance replacement therapy in 
primary immunodeficiency (PI), while IVIG 
is used for initiation and maintenance of 
replacement therapy and for the high doses 
required in immunomodulatory therapy. 
However, SCIG has the potential to play a more 
important role in indications besides PI, such as 
neuropathies and myopathies. Here, the authors 
review emerging developments in the use 
of SCIG.
METHODS
Studies presented here were selected for their 
contribution to the development of SCIG 
therapy beyond the established clinical practice, 
based on the authors’ experience in the field. 
An initial PubMed search was performed using 
the terms immunoglobulin, immune globulin, 
subcutaneous, PI, chronic inflammatory 
demyelinating polyradiculoneuropathy 
(CIDP), multifocal motor neuropathy (MMN), 
myasthenia gravis, Kawasaki disease, immune 
thrombocytopenia, and Guillain-Barré 
syndrome, without restriction to publication 
date or publication language.
SCIG IN INITIATION OF 
REPLACEMENT THERAPY
Traditionally, maintenance replacement SCIG 
therapy is preceded by a switch from existing 
IVIG therapy. Different regimens for initiating 
SCIG have been tested, but usually the first 
subcutaneous infusion is given 1 week after the 
last intravenous infusion in order to maintain 
high serum IgG levels.13-15 Thereafter, the 
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average daily IgG level achieved with IVIG 
can be maintained with regular subcutaneous 
infusions (Figure 1). Alternatively, however, the 
IgG loading can be achieved directly with SCIG.
Study of SCIG in Previously Untreated 
Patients with PI
A recently completed open-label, single-arm, 
phase 2 study of Vivaglobin® (CSL Behring 
GmbH, Marburg, Germany), a 16% SCIG, in 
previously untreated patients with PI, showed 
that initial IgG loading of patients can be easily 
achieved with daily SCIG administration.16
Eighteen patients (aged 2-65 years) received 
an initial loading dose of 100 mg/kg body 
weight/day for 5 consecutive days followed 
by maintenance therapy with 100-200 mg/kg 
weekly (Figure 2A). Seventeen patients (94%) 
achieved the target serum IgG level of ≥5 g/L by 
day 12 (1 week after completion of the loading 
dose) and one patient achieved the target 
IgG level by day 26. Mean IgG levels increased 
more than twofold from screening to day 12 
(Figure 2B)16 and remained stable for the entire 
6-month maintenance phase of the study. 
The study design allowed dose adjustments 
in week 3; however, no patient required dose 
adjustment. The doses chosen at study start 
were maintained throughout the study and 
were effective in all patients. 
Treatment was well tolerated, with 98% of 
AEs being mild or moderate. Similar tolerability 
has been reported in PI patients switched 
from IVIG to Vivaglobin in another study: 
in 60 patients, of whom 16 were children, 
98% of local reactions and 86% of subcutaneous 
infusion-related systemic AEs were mild, with 
only one severe systemic AE (hypotension).14
The results from this study showed that 
protective IgG levels are achieved by initiating 
SCIG treatment directly, without prior IVIG 
loading, creating new treatment possibilities for 
patients with PI.
SCIG in Immunomodulation
Immunoglobulin treatment is considered 
the first choice of therapy in a number of 
autoimmune or inflammatory diseases. A 
recent report of the United Kingdom (UK) 
National Immunoglobulin Database identified 
idiopathic/autoimmune thrombocytopenia as 
the major hematological indication in which 
immunoglobulin has been used in the UK 
between 2008-2009.17 In neurological indications, 
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Figure 1. Schematic presentation of serum IgG levels 
achieved with intravenous and/or subcutaneous 
administration. Serum IgG levels are presented 
schematically to illustrate the different rate of IgG increase 
with different administration routes and regimens. The 
curves labeled IVIG and SCIG refer to treatment with 
IVIG or SCIG alone, without loading. The shaded area 
marked “Higher risk zone between two IVIG infusions” 
denotes the waning period of treatment effect, resulting 
in increased rate of infections in PI or deteriorating 
muscle strength in MMN. IgG=immunoglobulin G; 
IVIG=intravenous immunoglobulin; MMN=multifocal 
motor neuropathy; PI=primary immunodeficiency; 
SCIG=subcutaneous immunoglobulin.
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85% of immunoglobulin use has been reported in 
CIDP, MMN, myasthenia gravis, or Guillain-Barré 
syndrome.17 In the recently initiated Assessment 
of Immunoglobulins in a Long-Term Non-
Interventional Study (SIGNS), the use of IVIG and 
SCIG in immunodeficiencies and neurological 
autoimmune indications will be evaluated.18
An updated summary of mechanisms of action 
and indications for use of immunoglobulin 
therapy in immunomodulation have been 
published recently.19 It is not clear which of the 
many immunomodulatory mechanisms of IgG 
are responsible for its effects in neuropathies or 
myopathies.20,21 Effective immunomodulation 
is traditionally associated with high IgG doses, 
although these are not based on actual dose-
finding studies. For most conditions, it has 
been assumed that the dose used in Kawasaki 
syndrome and immune thrombocytopenia 
(2 g/kg) is needed. It is unknown whether 
high peaks are necessary for treatment effect, 
but in several conditions – particularly in 
neuromuscular diseases – patients experience 
recurrent symptoms (muscle weakness) at 
low trough levels when the next intravenous 
infusion is due.22 Studies involving several 
indications have been initiated to determine 
whether equivalent-dose SCIG could be as 
effective as IVIG; eliminating these low troughs 
and the attendant increase in symptoms.23-29
The use of SCIG instead of IVIG in 
maintenance therapy in MMN, polymyositis, and 
dermatomyositis has been reported recently.30-34
Crossover study of SCIG and IVIG in MMN
In a randomized, single-blinded, crossover 
study, nine MMN patients who showed a good 
response to previous IVIG therapy were enrolled. 
Responsiveness to IgG therapy was defined as a 
Figure 2. Initialization of SCIG therapy in previously untreated primary immunodeficiency (PI) patients. (A) PI study 
design. Dose adjustments in patients not achieving serum IgG levels of ≥5 g/L by day 12 were planned for day 15 (an 
additional dose of 150 mg/kg bw) and day 19 (a dose increased to 150 mg/kg). Reproduced from Borte M et al.,16 J Clin 
Immunol 2011; Sep 20. [Epub ahead of print] (Fig. 1), with kind permission from Springer Science+Business Media B.V.  
(B) Increase in serum IgG levels after five consecutive daily doses of 100 mg/kg SCIG. Mean ± SD serum levels are shown. 
The arrow indicates the target for primary endpoint: IgG levels >5 g/L at day 12. bw=body weight; IgG=immunoglobulin 
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decrease of ≥10% in combined dynamometric 
strength of one or more muscle groups in a 
prestudy, treatment-free period of a maximum 
10 weeks.32 Prior to entering the main study, 
muscle strength was restored by administering 
two IVIG doses as a “wash-out” treatment prior 
to the main study. In the main study, patients 
were randomized to receive SCIG (Subcuvia®, 
Baxter International Inc., Deerfield, IL, USA) 
or IVIG (Endobulin®, Baxter International Inc.) 
for a period equivalent to three IVIG treatment 
intervals (18-56 days) and then switched to 
the other treatment. SCIG was administered 
two to three times weekly, while IVIG was 
given at individually adjusted intervals. The 
two treatments were equally effective and 
the combined dynamometric strength was 
maintained in eight of nine patients during each 
intervention period; one patient was poorly 
compliant. Thus, SCIG was as effective as IVIG 
in short-term treatment. Transient injection site 
reactions during SCIG treatment were reported 
by six patients, but only one patient experienced 
sustained erythema and edema at the injection 
site that necessitated temporary reduction of 
the injected volume. Three patients on IVIG 
reported AEs: rash, phlebitis, and venous 
catheter infection.32
Dose-Finding Study of SCIG in MMN
In a single-center, open-label study, 10 patients 
with MMN were treated one to two times a 
week for 6 months with SCIG (GammaQuin®, 
Sanquin, Amsterdam, The Netherlands) at 
monthly doses equivalent to either 50% or 
100% of the previous IVIG dose (five patients 
in each group).31 In case of worsening of disease 
symptoms, the low dose could be doubled. 
The primary endpoint was muscle strength in 
10 predefined bilateral muscle groups, evaluated 
using the Medical Research Council Scale. 
In the low-dose group, one patient discontinued 
the study due to injection site reactions (local 
swelling and pain) and the remaining four 
patients experienced deteriorating muscle 
strength and had to be reloaded with IVIG, 
which resulted in improvement. Four of 
five patients in the equivalent-dose group 
maintained muscle strength throughout the 
study. The fifth patient was administered an 
IVIG loading dose and, because of the patient’s 
preference for an SCIG treatment, maintained 
on a higher SCIG dose (166% of the previous 
IVIG dose) with which muscle strength 
remained stable. The treatment was tolerated 
well, with no serious AEs and decreasing 
incidence of local reactions during therapy.
Smooth Transition Protocol Study of SCIG 
in MMN
A recently completed prospective, open-label, 
multicenter, phase 2 study in patients with 
MMN showed that IgG concentrations can be 
maintained over 6 months with weekly SCIG 
(Vivaglobin) administration using a protocol in 
which the dose of SCIG was increased weekly 
to maintain the serum IgG levels achieved 
with prior IVIG therapy (smooth transition 
protocol).34 After an initial run-in period, 
eight patients aged 42-66 years on stable 
IVIG treatment received weekly subcutaneous 
Vivaglobin infusions for 24 weeks (Figure 3A)34
at doses equivalent to the calculated weekly 
IVIG dose from previous therapy. The dose 
was adjusted stepwise during the first month 
to achieve a smooth transition of the total 
administered IgG dose from monthly IVIG 
treatment to weekly SCIG infusions. With a 
mean dose of 272 mg/kg/week (corresponding 
to 1087 mg/kg/month), seven of eight patients 
maintained serum IgG levels (14-22 g/L) 
similar to those at study start and had stable or 
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Figure 3. Maintenance therapy with SCIG in MMN patients. (A) MMN study design. Dose increases of 25% in patients 
with deteriorating muscle strength were planned for week 8 or 16. Reproduced from Misbah S et al.,34 J Peripher Nerv Syst 
2011;16:92-97 (Fig. 1), with kind permission from John Wiley & Sons Ltd. (B) Maintenance of muscle strength. Muscle 
strength scores at baseline and week 24 are shown. The strengths of 40 standardized muscles or muscle groups of the upper 
and lower limbs (20 on each side) were assessed according to the MRC Scale. The full scale ranges from 0-200 points, with 
200 meaning normal muscle power. Patient 2 (red cross) discontinued at week 12 due to progressive worsening despite 
dose increase. (C) Clinical scores as function of IgG trough levels in one patient who discontinued due to treatment 
failure. Worsening in muscle strength, disability score and motor function score, in the MMN patient who discontinued 
due to treatment failure is shown together with serum IgG concentrations (IgG and motor function data available only for 
baseline and week 8 due to discontinuation after week 12). Muscle strength score was determined as described for Figure 3B. 
Disability was assessed using a modified Guy’s Neurological Disability scale. The scale ranges from 0-10 points, with  
10 meaning inability to use arms and legs. Motor function score was based on 4 individually defined tasks. The scale ranges 
from 0-16 points, with 16 meaning inability to perform any task. IVIG=intravenous immunoglobulin; MMN=mutifocular 
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somewhat improved muscle strength (Figure 3B). 
One patient’s muscle strength and disability 
worsened despite dose increase, resulting in 
withdrawal from the study (Figure 3C). This 
patient had a body mass index indicative of 
cachexia (<17.5 kg/m²), suggesting that IgG 
absorption from the subcutaneous sites may have 
been suboptimal. Patients felt comfortable with 
self-infusion and tolerated SCIG administration 
well. Four patients did not experience any AEs. 
No severe AEs were reported and 89% of all 
AEs were mild. Only one patient experienced 
injection site reactions (edema, pruritus, and 
skin reaction). The results of this study suggest 
that rapidly raising peak IgG concentrations, as 
achieved with intravenous administration, may 
not be required for ongoing clinical efficacy 
in MMN. Due to the small number of patients 
in the study, the results need to be verified 
and expanded to other diseases requiring 
immunomodulatory therapy.
SCIG Therapy in Other Neuropathies
Two case reports of the use of SCIG in the 
maintenance of CIDP demonstrated stabilization 
of patients with monthly doses equivalent to 
previous IVIG treatment.33 The weekly dose was 
administered either once per week or on three 
consecutive days per week. Tolerability was 
good, with only local reactions observed.
Initiation of immunomodulation therapy 
with SCIG in patients with polymyositis or 
dermatomyositis was reported recently.30
Although six of the seven patients had been 
treated with IVIG at some point, four were not 
receiving IVIG at the start of the study. In these 
patients, SCIG therapy was initiated by once 
weekly administration of 0.2 g/kg/week, resulting 
in improved serum creatine kinase levels and 
muscle strength.30 Apart from mild local reactions 
in two patients, no major AEs were observed.
DISCUSSION
The Importance of Stable Trough IgG Levels
Despite the small patient populations in the 
studies described above, it appears that both 
intravenous and subcutaneous regimens can be 
used in the initiation of replacement therapy in 
PI and maintenance of patients with MMN.
It has been suggested that a minimal IgG 
concentration (5 g/L) is required for protection 
from infections in immunodeficiencies35-37
and that higher serum IgG levels result in 
better protection.38-40 Thus, achievement of an 
optimal serum IgG level has become a primary 
target of therapy.41 Patient databases, such as 
the European Society for Immunodeficiencies 
(ESID) online registry, clearly suggest improved 
efficacy at higher serum IgG levels. For 
example, in patients with common variable 
immunodeficiency, infection rate and number 
of days spent in hospital decrease substantially 
as IgG levels increase from <5 g/L to >7 g/L.41
In two recent studies of IgPro20 (Hizentra®, 
CSL Behring, Berne, Switzerland) in PI, using 
median IgG doses of 113.9 and 213.2 mg/kg,42,43
mean IgG trough levels of 8.10 and 12.53 g/L, 
respectively, were achieved. There were no 
serious infections and the corresponding rates 
of non-serious infections were 5.18 versus 
2.76 infections/patient/year, respectively. 
The correlation between IgG levels and 
clinical outcomes in MMN is illustrated 
with data for one patient from the smooth 
transition protocol study, whose IgG levels 
failed to increase, probably due to the low 
body fat, with associated worsening of disease 
symptoms (see Figure 3C).34 It remains to be 
established whether stable IgG trough levels are 
as effective in autoimmune-mediated disorders 
as they are in PI. After the pioneering work of 
Imbach et al. in immune thrombocytopenia,44
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clinicians have used similar high doses of IVIG, 
without dose ranging or alternative treatment 
schedule studies, for the successful treatment 
of other disorders with autoimmune and/or 
inflammatory pathogenesis.
Active Choice for Patients
With increasingly widespread use of SCIG, 
patients have the opportunity to choose a 
treatment schedule to fit a lifestyle, family 
activities, and personal preference. Physicians 
should take into account both clinical and 
lifestyle factors when selecting the route of 
administration (Table 1). Important clinical 
factors are venous access and the tolerability 
of the IgG product used.45 Particular emphasis 
should be placed on the timely and thorough 
patient characterization to ensure that risk 
factors for AEs are identified before treatment 
with IVIG or SCIG is chosen. Underlying 
conditions predisposing to acute renal 
insufficiency after IVIG administration have 
been adequately described and may include 
renal insufficiency, diabetes mellitus, volume 
depletion, sepsis, paraproteinemia, high titer 
of rheumatoid factor, and advanced age.46 High 
serum viscosity may lead to vascular events such 
as thromboembolism and a history of migraine 
has been associated with an increased risk of 
aseptic meningitis after IVIG.46-48
Patients’ attitudes to IVIG and SCIG are based 
on both preferences and concerns. Patients who 
live at a distance from doctor’s office or infusion 
center, as well as those who are employed or 
travel frequently usually prefer to infuse at 
home. Patients making this choice are willing to 
complete the training and take responsibility for 
the treatment. A preference for clinic or infusion 
center IVIG therapy is observed among the 
elderly, the unemployed, those with aversion to 
needles, and those with fear of facing potential 
AEs at home.11,12,49,50 Some patients prefer home 
therapy regardless of the administration route11
and in that case SCIG therapy may often be 
more appropriate. The safety and security of 
the patient’s home environment, the patient’s 
schedule and availability during business hours, 
and the level of support the patient receives 
from family and physician are crucial factors in 
decision making. In addition, selecting one route 
of administration over the other must take into 
consideration the different AE profiles of IVIG 
and SCIG products: IVIG is more frequently 
associated with systemic AEs, such as headache, 
nausea, and fatigue;51 SCIG administration is 
largely free of these AEs, but may cause infusion 
site reactions, such as swelling and redness.36
The treatment options available in clinical 
practice are extremely diverse. The same IgG 
dose can be administered in several different 
ways depending on the patient’s preference. Slow 
overnight administration, fast infusion with two 
pumps (less than 1 hour), and frequent, rapid 
manual (push) infusions all are viable options. 
With the frequent push method, a volume of 
3-20 mL of Vivaglobin can be easily administered 
daily or on alternate days without the cost or 
complications of a mechanical pump.21,22
New Products Allow Faster Subcutaneous 
Infusions
Preparations for intramuscular immunoglobulin 
(IMIG) administration were the first products 
to be infused subcutaneously.8,9,52 Infusions 
were initially very slow (10-20 mL over several 
hours), but as the improved tolerability of 
SCIG was recognized, infusion rates were 
increased.3,11,53 Currently available 16% 
products are infused at 10-20 mL (1.6-3.2 g) per 
hour (Table 2).14,15 The recent introduction of a 
20% product (Hizentra), specifically formulated 
for subcutaneous use, allowed even higher 
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Table 1. Key features of intravenous immunoglobin (IVIG) and subcutaneous immunoglobin (SCIG).
IVIG SCIG
Efficacy
Stable serum IgG levels No Yes
Peak serum IgG Yes No
Protection from infections Yes Yes
Tolerability
Treatment-associated systemic adverse events Yes None or very rare
Treatment-related local reactions None or very rare Yes
Administration specifics
Need for venous access Yes No
Duration of infusion Several hours Typically 1 hour or less
Frequency of infusions Once every 2-4 weeks Typically once a week (ranges from 
once a day to once every 2 weeks)
Convenience
Self-infusion Yes (but more technically 
demanding)
Yes (preferred by most patients, 
especially children)
Home administration Yes (but now less frequently chosen) Yes (preferred by most patients)
Training for home therapy Yes (longer and more technically 
demanding, need for good veins)
Yes (typically achieved during first 
3-4 training sessions
Flexibility for the patients Yes (2-4 weekly administrations are 
necessary)
Yes (once daily, 2-4 times per week, 
once weekly, once every 2 weeks; 
pump or push infusion)
Suitable for active life style (employment, school, 
sports, frequent travel, etc)
Yes (chosen by some patients 







Autoimmune or inflammatory conditions 
(“high-dose” indications)
Yes Yes, increasingly used in 
neurological indications
Initiation of immunoglobulin therapy Yes Yes, evaluated in primary 
immunodeficiencies
Maintenance immunoglobulin therapy Yes Yes
IgG=immunoglobulin G.
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flow rates: up to 50 mL (10 g) per hour42 or 
70 mL (14 g) per hour43 without compromising 
local tolerability in two phase 3 trials. 
Other tools for optimization are based on 
techniques previously used in the infusion of 
other subcutaneous medications. Hyaluronidase 
of animal origin has been used to increase tissue 
permeability by partial degradation of the 
extracellular matrix, which is a significant barrier 
to subcutaneous delivery. The development of 
recombinant human hyaluronidase (rHuPH20) 
has also opened new possibilities for IgG 
administration.21,54,55 Implanted subcutaneous 
infusion ports may help the infused fluid 
to distribute more evenly into the tissue; 
thus, potentially allowing increased volumes 
and shortened infusion times. However, 
with any implanted device in the setting of 
immunodeficiency, the risk of infection would 
need to be considered.
Subcutaneous Administration and 
Home Therapy Reduce the Cost of 
Immunoglobulin Treatment
Several studies have compared the costs of IgG 
treatment with subcutaneous versus intravenous 
and home versus hospital/office administration. 
The total yearly cost of home therapy was 
found to be 50% of the cost of hospital-based 
therapy in Sweden, Denmark, and Norway, 
and the out-of-pocket costs of patients were 
reduced by 85%.53 However, the reduction in 
costs was partially due to the substantially lower 
price of the IMIG used for the subcutaneous 
route. In Germany, SCIG treatment was found 
to be less expensive than IVIG treatment by 
approximately 50% due to the substantially 
reduced costs for treatment and diagnostic 
procedures, as well as the time for sick leave 
of caregivers of pediatric patients.56 A therapy-
related cost reduction of 50% was reported in 
two case studies of patients with CIDP who 
switched from IVIG to SCIG receiving equivalent 
doses.33 A study performed by the Canadian 
Government Agency for Drugs and Technologies 
in Health (CADTH) provided data showing that 
home administration of IVIG or SCIG in patients 
with PI in Canada would be more cost-effective 
than hospital/office administration: the overall 
costs for self-administered IVIG (100%) and self-
administered SCIG (103.6%) were lower than 
the costs for conventional hospital-administered 
IVIG therapy (113.5%).57 Thus, there remain 
potential savings that are independent of route, 
home administration, and drug costs.
More pharmacoeconomic studies in Europe 
and the USA will be needed to evaluate the 
costs of immunoglobulin treatment, including 
products, healthcare personnel, hospital and 
facility charges, and infusion equipment, which 
add to the overall costs of treatment.58 These 
studies should take into consideration the value 
to the patient and family of costs now required 
for travel to the office or clinic, and time spent 
waiting for IVIG administration. The current 
clinical practice gives the general perception 
that home therapy and/or self-infusion are 
cost-neutral in most countries, but offer the 
added benefit of improvements to patients’ 
quality of life.12,59 Additional potential sources 
of cost reduction with optimal immunoglobulin 
replacement therapy are the improved treatment 
efficacy and good tolerability of the currently 
used products, resulting in lower costs for 
the treatment of disease-specific symptoms 
(eg, recurrent infections in patients with PI), 
maintenance of the ability to ambulate and 
conduct activities of daily living (in neuropathies/
myopathies), and alleviation or treatment of AEs. 
A potential source of increased cost for SCIG 
therapy in the US would be the current Food and 
Drug Administration (FDA) recommendation to 
use higher doses than the previous IVIG dose.
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CONCLUSION
A number of IgG treatment options are now 
available, with the development of high-quality 
new products for intravenous and subcutaneous 
administration. SCIG therapy appeals to many 
patients with its simple integration into everyday 
life, shorter training period for home therapy, 
and flexibility. The potential applicability 
of SCIG for indications beside PI, such as 
neuropathies, myopathies, and autoimmune 
or inflammatory disorders should allow it to 
play a more prominent role in areas currently 
reserved only for IVIG. Patients are increasingly 
aware of the treatment possibilities for a disease 
and are more willing to take responsibility 
for the treatment in exchange for flexibility. 
Improving choice amongst treatment options 
requires ongoing support from physicians 
and nurses in patient education and training, 
improving the availability of equipment and 
healthcare personnel, and providing a flexible 
individualized package of care for patients.
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